We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Viral Marker Predicts Flu Severity in Infected Patients

By LabMedica International staff writers
Posted on 01 Nov 2017
Influenza A viruses are the causative agents of annual epidemics, sporadic zoonotic outbreaks and occasionally pandemics. More...
Worldwide, acute respiratory infections caused by influenza A viruses continue to be one of the main causes of acute illness and death.

Influenza is particularly dangerous for infants, the elderly, and people with underlying medical issues, but otherwise-healthy people sometimes experience severe infection, too. Markers of severity have been found for specific strains, but a general marker that applies to multiple strains would be more useful to inform treatment and policy.

A team of scientists at the Spanish National Center for Biotechnology (Madrid, Spain) included in their study patients in a severe/fatal cohort who were influenza A(H1N1)pdm09 confirmed cases, aged over four and less than 65 years old, admitted to intensive care unit (ICU) and with the information related to risk factors reflected in their clinical history. Those patients who developed highly severe disease did not display any comorbidities associated to severe influenza A virus infection, and deceased patients presented some comorbid conditions. Mild patients were influenza A(H1N1)pdm09 confirmed cases, aged over four and less than 65 years old, who developed mild disease and were monitored by sentinel medical centers.

The team focused on defective viral genomes (DVGs), which consist of pieces of viral RNA with missing genetic information, which are found in multiple strains of influenza virus. To test whether DVGs could serve as a general marker of influenza severity, they infected both mice and human tissue cell cultures with different strains of influenza A H1N1 virus, the subtype responsible for influenza pandemics.

The team also analyzed the genomes of viruses isolated from respiratory samples taken from people who experienced severe infection or death during the 2009 "swine flu" pandemic or later "swine flu-like" seasons. The identity of rescued mutant viruses was ascertained by sequencing of DNAs derived from the polymerase genes PA and PB2 RNA segments by reverse transcription-PCR (RT-PCR) amplification. Quality and quantity of each RNA preparation was monitored using the Agilent 2100 Bioanalyzer. Flow cytometric analysis was performed on a cytometer LSR II.

The team found that the H1N1 strain that caused severe symptoms had significantly less DVG accumulation than influenza A strains sampled from people who experienced only mild symptoms. Together, these results suggest that low levels of DVGs may indicate greater risk of severe disease in patients infected with influenza A virus. With further studies, these findings could help predict influenza severity, guide patient treatment, and inform influenza prevention strategies. The study was published on October 12, 2017, in the journal Public Library of Sciences Pathogens.

Related Links:
Spanish National Center for Biotechnology


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.